Cargando…

Clinical and Microbiological Profile of Pathogens in Febrile Neutropenia in Hematological Malignancies: A Single Center Prospective Analysis

Background. Febrile neutropenia is the consequence of treatment of hematological disorders. The first-line empirical treatment should cover the prevalent microorganism of the institute. The aim of study was to establish the effectiveness of current practices used at the institution and to review the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taj, M., Farzana, T., Shah, T., Maqsood, S., Ahmed, S. S., Shamsi, T. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531203/ https://www.ncbi.nlm.nih.gov/pubmed/26290665 http://dx.doi.org/10.1155/2015/596504

Ejemplares similares

Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients
por: Lakshmaiah, Kuntegowdanahalli C, et al.
Publicado: (2015)

Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode
por: Demirel, Aslıhan, et al.
Publicado: (2015)

Update on the management of febrile neutropenia in hematologic patients
por: Escrihuela-Vidal, Francesc, et al.
Publicado: (2019)

Diagnostic Radiology in Hematological Patients with Febrile Neutropenia
por: Heussel, Claus Peter
Publicado: (2014)

Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
por: Villafuerte-Gutierrez, Paola, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
por: Álvarez, José C., et al.
Publicado: (2021)

Evaluation of Bloodstream Infections During Chemotherapy-Induced Febrile Neutropenia in Patients with Malignant Hematological Diseases: Single Center Experience
por: Piukovics, Klára, et al.
Publicado: (2015)

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
por: Álvarez, José C, et al.
Publicado: (2013)

Corrigendum to “Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update”
por: Villafuerte-Gutierrez, Paola, et al.
Publicado: (2019)

Remote Monitoring of Patients With Hematologic Malignancies at High Risk of Febrile Neutropenia: Exploratory Study
por: Kroloff, Maxwell, et al.
Publicado: (2022)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015)

Altered Pharmacokinetics Parameters of Vancomycin in Patients with Hematological Malignancy with Febrile Neutropenia, a Bayesian Software Estimation
por: Alzahrani, Abdullah M., et al.
Publicado: (2023)

Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients
por: Koizumi, Yusuke, et al.
Publicado: (2017)

Evaluation of Using Empiric Glycopeptides in Accordance with the IDSA Guidelines in Hematologic Malignancy Patients with Febrile Neutropenia
por: Yalçın, Cumali, et al.
Publicado: (2022)

The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies
por: Çalık, Şebnem, et al.
Publicado: (2018)

Sepsis and neutropenia in hematological malignancies
por: Labiad, Y, et al.
Publicado: (2014)

1257. A phase II Prospective Randomized Study to Assess Ceftolozane-Tazobactam in the Management of Febrile Neutropenia in Patients with Hematological Malignancies
por: Chaftari, Anne-Marie, et al.
Publicado: (2020)

FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients—efficacy and microbiologic safety
por: Moreno, Ainhoa Fernández, et al.
Publicado: (2023)

Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change
por: Mebis, J, et al.
Publicado: (2010)

Investigation of seasonal frequency and pathogens in febrile neutropenia
por: Özdemir, Seray Karagöz, et al.
Publicado: (2019)

Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia
por: Teofili, Luciana, et al.
Publicado: (2016)

Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy
por: Nishi, Hiromi, et al.
Publicado: (2022)

Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies
por: Ohashi, Takashi, et al.
Publicado: (2022)

Influence of Febrile Neutropenia Period on Plasma Viscosity at Malignancy
por: Tek, Ibrahim, et al.
Publicado: (2013)

Comparison of the etiologic, microbiologic, clinical and outcome characteristics of febrile vs. non-febrile neutropenia in hospitalized immunocompetent children
por: Leibovitz, Eugene, et al.
Publicado: (2020)

Novel Biomarker Candidates for Febrile Neutropenia in Hematological Patients Using Nontargeted Metabolomics
por: Lappalainen, Marika, et al.
Publicado: (2018)

The role of presepsin in pediatric patients with oncological and hematological diseases experiencing febrile neutropenia
por: Cerasi, Sara, et al.
Publicado: (2023)

Safety and Efficacy of Antibiotic De-escalation and Discontinuation in High-Risk Hematological Patients With Febrile Neutropenia: A Single-Center Experience
por: Verlinden, Anke, et al.
Publicado: (2021)

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
por: Naeem, Doaa, et al.
Publicado: (2018)

Febrile neutropenia: significance of elaborated screening for respiratory viruses, and the comparison of different sampling methods, in neutropenic patients with hematological malignancies
por: Jansen, Rogier R, et al.
Publicado: (2013)

The Value of Metagenomic Next-Generation Sequencing in Hematological Malignancy Patients with Febrile Neutropenia After Empiric Antibiotic Treatment Failure
por: Zhang, Meng, et al.
Publicado: (2022)

Ceftolozane-Tazobactam for Febrile Neutropenia Treatment in Hematologic Malignancy Patients Colonized by Multi-Resistant Enterobacteriaceae: Preliminary Results from a Prospective Cohort Study
por: Marchesi, Francesco, et al.
Publicado: (2020)

Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia
por: Korpelainen, Sini, et al.
Publicado: (2017)

Evaluating the Use of Meropenem in Hematologic Patients with Febrile Neutropenia: A Retrospective Observational Single-Cohort Study
por: Stuurman, R.A., et al.
Publicado: (2023)

Management of Febrile Neutropenia: A Description of Clinical and Microbiological Findings by Focusing on Risk Factors and Pitfalls
por: Karimi, Fatemeh, et al.
Publicado: (2018)

Reducing Repeat Blood Cultures in Febrile Neutropenia: A Single-Center Experience
por: Robinson, Evan D, et al.
Publicado: (2022)

Developments in the management of febrile neutropenia
por: Pascoe, J
Publicado: (2011)

Febrile neutropenia with bacterial paronychia
por: Hosono, Yuki, et al.
Publicado: (2018)

Febrile Neutropenia in Transplant Recipients
por: Nesher, Lior, et al.
Publicado: (2018)

Febrile Neutropenia in Children with Cancer
por: Paulus, Stéphane, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1kjs6pg722oia3688dpr8js9g1